Bernie Schuler
Directeur/Membre du Conseil chez Bridgepoint GmbH
Profil
Bernie Schuler currently works at Bridgepoint GmbH, as Managing Director from 2011.
Mr. Schuler also formerly worked at Xellia Pharmaceuticals AS, as Director and 3i Private Equity, as Partner from 1996 to 2011.
Mr. Schuler received his undergraduate degree from Claremont McKenna College and Masters Business Admin degree from the University of California, Berkeley.
Postes actifs de Bernie Schuler
| Sociétés | Poste | Début |
|---|---|---|
| Bridgepoint GmbH | Directeur/Membre du Conseil | 14/06/2011 |
Anciens postes connus de Bernie Schuler
| Sociétés | Poste | Fin |
|---|---|---|
3i Private Equity
 3i Private Equity Investment ManagersFinance 3i Private Equity is a private equity firm, founded in 1945. The firm is headquartered in London, United Kingdom with additional offices around the world. | Corporate Officer/Principal | 01/01/2011 |
Xellia Pharmaceuticals AS
 Xellia Pharmaceuticals AS Pharmaceuticals: MajorHealth Technology Xellia Pharmaceuticals AS develops, manufactures, and supplies pharmaceutical drugs. The firm engages in the filed of biotechnology, synthetic organic chemistry development, and analytical development. The company was founded in 1946 and is headquartered in Oslo, Norway. | Directeur/Membre du Conseil | - |
Formation de Bernie Schuler
| Claremont McKenna College | Undergraduate Degree |
| University of California, Berkeley | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
3i Private Equity
3i Private Equity Investment ManagersFinance 3i Private Equity is a private equity firm, founded in 1945. The firm is headquartered in London, United Kingdom with additional offices around the world. | Finance |
Xellia Pharmaceuticals AS
Xellia Pharmaceuticals AS Pharmaceuticals: MajorHealth Technology Xellia Pharmaceuticals AS develops, manufactures, and supplies pharmaceutical drugs. The firm engages in the filed of biotechnology, synthetic organic chemistry development, and analytical development. The company was founded in 1946 and is headquartered in Oslo, Norway. | Health Technology |
| Bridgepoint GmbH | Finance |
